Siri Atma W. Greeley to Hypoglycemic Agents
This is a "connection" page, showing publications Siri Atma W. Greeley has written about Hypoglycemic Agents.
Connection Strength
1.706
-
Response letter to the editor. J Clin Endocrinol Metab. 2015 Jan; 100(1):L14.
Score: 0.411
-
Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons. J Clin Endocrinol Metab. 2014 Dec; 99(12):E2709-14.
Score: 0.409
-
Using a Do-It-Yourself Artificial Pancreas: Perspectives from Patients and Diabetes Providers. J Diabetes Sci Technol. 2020 09; 14(5):860-867.
Score: 0.151
-
Precision Medicine: Long-Term Treatment with Sulfonylureas in Patients with Neonatal Diabetes Due to KCNJ11 Mutations. Curr Diab Rep. 2019 06 27; 19(8):52.
Score: 0.140
-
Neonatal Diabetes Mellitus: An Update on Diagnosis and Management. Clin Perinatol. 2018 03; 45(1):41-59.
Score: 0.126
-
Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes. Diabetologia. 2015 Jul; 58(7):1430-5.
Score: 0.105
-
Successful transition from insulin to sulfonylurea therapy in a patient with monogenic neonatal diabetes owing to a KCNJ11 F333L [corrected] mutation. Diabetes Care. 2013 Dec; 36(12):e201.
Score: 0.095
-
Neonatal diabetes: an expanding list of genes allows for improved diagnosis and treatment. Curr Diab Rep. 2011 Dec; 11(6):519-32.
Score: 0.083
-
Neonatal diabetes mellitus: a model for personalized medicine. Trends Endocrinol Metab. 2010 Aug; 21(8):464-72.
Score: 0.074
-
Update in neonatal diabetes. Curr Opin Endocrinol Diabetes Obes. 2010 Feb; 17(1):13-9.
Score: 0.073
-
Long-term Follow-up of Glycemic and Neurological Outcomes in an International Series of Patients With Sulfonylurea-Treated ABCC8 Permanent Neonatal Diabetes. Diabetes Care. 2021 01; 44(1):35-42.
Score: 0.039